These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37497829)

  • 1. mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis.
    Monich AG; Cunha MFMD; Barreto FC
    J Bras Nefrol; 2023; 45(4):503-505. PubMed ID: 37497829
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.
    Coombs EJ
    J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.
    Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA
    Nephron; 2016; 134(2):51-58. PubMed ID: 27504842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC).
    Brakemeier S; Vogt L; Adams L; Zukunft B; Diederichs G; Hamm B; Budde K; Makowski MR
    PLoS One; 2017; 12(12):e0189132. PubMed ID: 29232371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease.
    Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N
    Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
    Budde K; Gaedeke J
    Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition.
    Kronick J; Gabril MY; House AA
    Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tuberous sclerosis complex-associated kidney angiomyolipoma: from contemplation to action.
    Pirson Y
    Nephrol Dial Transplant; 2013 Jul; 28(7):1680-5. PubMed ID: 23413089
    [No Abstract]   [Full Text] [Related]  

  • 9. The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex.
    Barnett JR; Grinspoon RA; Harisinghani M; Caruso PA; Thiele EA
    J Clin Neurosci; 2020 Jul; 77():85-88. PubMed ID: 32409220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition.
    Krummel T; Garnon J; Lang H; Gangi A; Hannedouche T
    BMC Urol; 2014 Sep; 14():77. PubMed ID: 25258166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
    Samuels JA
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.
    Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R
    Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular insights into tuberous sclerosis complex renal disease.
    Siroky BJ; Yin H; Bissler JJ
    Pediatr Nephrol; 2011 Jun; 26(6):839-52. PubMed ID: 21152937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric Renal Angiomyolipomas in Tuberous Sclerosis Complex.
    Warncke JC; Brodie KE; Grantham EC; Catarinicchia SP; Tong S; Kondo KL; Cost NG
    J Urol; 2017 Feb; 197(2):500-506. PubMed ID: 27678300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
    Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
    N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.
    Henske EP; Rasooly R; Siroky B; Bissler J
    Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Massive renal angiomyolipoma in tuberous sclerosis.
    Katz DS; Poster RB
    Clin Imaging; 1997; 21(3):200-2. PubMed ID: 9156309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus and tuberous sclerosis-associated renal angiomyolipomas.
    Krischock L; Beach R; Taylor J
    Arch Dis Child; 2010 May; 95(5):391-2. PubMed ID: 20457704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Patient with tuberous sclerosis and giant renal angiomyolipomas].
    Baños Madrid R; Garre Sánchez MC; Morán Sánchez S
    An Med Interna; 2005 Oct; 22(10):500-1. PubMed ID: 16411306
    [No Abstract]   [Full Text] [Related]  

  • 20. Malignant epithelioid renal angiomyolipoma in a patient with tuberous sclerosis.
    Radin R; Ma Y
    J Comput Assist Tomogr; 2001; 25(6):873-5. PubMed ID: 11711798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.